gusperimus Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

15-deoxyspergualin | 15-deoxyspergualin trihydrochloride | 1-amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione | bms-181173 | bmy-42215-1 | deoxyspergualin | (+/-)-deoxyspergualin | gusperimus | gusperimus hcl | gusperimus hydrochloride | gusperimus, (+-)-isomer | gusperimus trihydrochloride | heptanamide, 7-((aminoiminomethyl)amino)-n-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)- | nkt-01

Organizations (10)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Diabetes Mellitus, Type 1 (Phase 2)

Graft Rejection (Phase 2)

Granuloma (Phase 3)

Granulomatosis with Polyangiitis (Phase 2)

Kidney Diseases (Phase 2)

Lupus Nephritis (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue